argenx SE (BSP:A1RG34) Net Interest Income : R$755 Mil (TTM As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is argenx SE Net Interest Income?

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors. argenx SE's net interest income for the three months ended in Mar. 2025 was R$207 Mil. Its net interest income for the trailing twelve months (TTM) ended in Mar. 2025 was R$755 Mil.

argenx SE Net Interest Income Historical Data

The historical data trend for argenx SE's Net Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

argenx SE Net Interest Income Chart

argenx SE Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Interest Income

Get a 7-Day Free Trial

24.27

13.53

118.27

451.07

831.42

argenx SE Quarterly Data
	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Net Interest Income	Get a 7-Day Free Trial															191.14	206.62	221.01	119.71	207.19

argenx SE Net Interest Income Calculation

Net Interest Income for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was R$755 Mil.

argenx SE Net Interest Income Related Terms

Thank you for viewing the detailed overview of argenx SE's Net Interest Income provided by GuruFocus.com. Please click on the following links to see related term pages.

argenx SE Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (BSP:A1RG34) » Definitions » Net Interest Income

Comparable Companies

Traded in Other Exchanges

ARGX:USA ARGXb:UK 0QW0:UK 1AEA:Germany 1AE:Germany ARGX:Belgium ARGX:Austria

Address

Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB

Website

https://www.argenx.com

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

argenx SE Headlines

No Headlines